Skip to main content

HPN-217 *

HPN-217 is a B cell maturation antigen (BCMA)-targeting Tri-specific T cell Activating Construct (TriTAC®).

HPN-217 is being developed by Harpoon Therapeutics through Phase 1/2 clinical trials. AbbVie has an option to license worldwide exclusive rights to HPN-217 after completion of the Phase 1/2 trial. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities.

Type of Molecule




Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Multiple Myeloma in Relapse n/a
Phase 1